---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099891"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:12:44.116827+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam: Obicetrapib significantly reduces p-tau217 in ApoE4 carriers in BROADWAY

## Summary
- p-tau217 reduced in full analysis set (p=0.0019, n=1,515) and ApoE4 carriers (p=0.0215, n=367).
- ApoE4/E4 carriers showed 20.48% mean p-tau217 reduction vs placebo (p=0.010).
- Favorable trends observed in NFL, GFAP, p-tau181, and Aβ42/40 biomarkers.
- Safety in BROADWAY overall was comparable to placebo; AD analysis not independently evaluated.
- Company plans to discuss results with regulators and explore next steps for AD program.

## SEC filing metadata
- accession: 0000950170-25-099891
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017025099891/0000950170-25-099891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017025099891/nams-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099891
- JSON: https://secwatch.observer/filing/0000950170-25-099891.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099891.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.